Zusammenfassung
Leberfunktionsstörungen können häufig bei kritisch kranken Patienten auf der Intensivstation (ICU) beobachtet werden und haben eine hohe Morbidität und Mortalität zur Folge. Die häufigsten Formen der Leberfunktionsstörung an der ICU sind die Schockleber und die cholestatische Leberfunktionsstörung mit Inzidenzraten bis zu 10 % bzw. 30 %.
Beide Erkrankungen treten häufig als Folge einer Ischämie/Hypoxie meist im Rahmen eines kardiogenen Schocks, einer Sepsis oder eines septischen Schocks auf. Speziell im Fall der cholestatischen Leberdysfunktion wurden jedoch auch andere potenzielle Verursacher identifiziert. Dazu gehören neben zugrunde liegenden Krankheiten, wie chronische Lebererkrankungen oder Malignome, auch iatrogene Faktoren, wie z. B. parenterale Ernährung, hohe Beatmungsdrücke, chirurgische Eingriffe, verschiedene Medikamente und Bluttransfusionen.
Frühzeitiges Erkennen und Behandeln der zugrunde liegenden Ursache stellen bislang die einzigen etablierten Therapiemaßnahmen bei Schockleber und cholestatischer Leberfunktionsstörung dar.
Abstract
Liver dysfunction is frequently observed in critically ill patients. Its occurrence is associated with high morbidity and mortality. The most frequent entities of hepatic dysfunction in the intensive care unit are shock liver and cholestatic liver dysfunction with incidence rates up to 10 and 30 %, respectively.
Both conditions are frequently triggered by hypoxic and/or ischemic events, most commonly cardiogenic shock and sepsis/septic shock. However, several other potential contributors have been identified especially for cholestatic liver dysfunction. Apart from chronic liver diseases and malignancies, iatrogenic factors such as total parenteral nutrition, high pressure ventilation, surgical procedures, drugs and blood transfusions promote its occurrence.
In shock liver and in cholestatic liver disease, early detection and therapy of the underlying disease is the only established treatment.
Literatur
Kramer L, Jordan B, Druml W et al (2007) Incidence and prognosis of early hepatic dysfunction in critically ill patients – a prospective multicenter study. Crit Care Med 35:1099–1104
Henrion J, Descamps O, Luwaert R et al (1994) Hypoxic hepatitis in patients with cardiac failure: incidence in a coronary care unit and measurement of hepatic blood flow. J Hepatol 21:696–703
Henrion J, Schapira M, Luwaert R et al (2003) Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore) 82:392–406
Raurich JM, Llompart-Pou JA, Ferreruela M et al (2011) Hypoxic hepatitis in critically ill patients: incidence, etiology and risk factors for mortality. J Anesth 25:50–56
Fuhrmann V, Kneidinger N, Herkner H et al (2009) Hypoxic hepatitis: underlying conditions and risk factors for mortality in critically ill patients. Intensive Care Med 35:1397–1405
Henrion J, Minette P, Colin L et al (1999) Hypoxic hepatitis caused by acute exacerbation of chronic respiratory failure: a case-controlled, hemodynamic study of 17 consecutive cases. Hepatology 29:427–433
Fuhrmann V, Kneidinger N, Herkner H et al (2011) Impact of hypoxic hepatitis on mortality in the intensive care unit. Intensive Care Med 37:1302–1310
Whitehead MW, Hawkes ND, Hainsworth I et al (1999) A prospective study of the causes of notably raised aspartate aminotransferase of liver origin. Gut 45:129–133
Fuchs S, Bogomolski-Yahalom V, Paltiel O et al (1998) Ischemic hepatitis: clinical and laboratory observations of 34 patients. J Clin Gastroenterol 26:183–186
Hickman PE, Potter JM (1990) Mortality associated with ischaemic hepatitis. Aust N Z J Med 20:32–34
Drolz A, Jager B, Wewalka M et al (2013) Clinical impact of arterial ammonia levels in ICU patients with different liver diseases. Intensive Care Med 39:1227–1237
Jager B, Drolz A, Michl B et al (2012) Jaundice increases the rate of complications and one-year mortality in patients with hypoxic hepatitis. Hepatology 56:2297–2304
Birrer R, Takuda Y, Takara T (2007) Hypoxic hepatopathy: pathophysiology and prognosis. Intern Med 46:1063–1070
Drolz A, Horvatits T, Michl B et al (2014) Statin therapy is associated with reduced incidence of hypoxic hepatitis in critically ill patients. J Hepatol (in press)
Fuhrmann V, Jager B, Zubkova A et al (2010) Hypoxic hepatitis – epidemiology, pathophysiology and clinical management. Wien Klin Wochenschr 122:129–139
Henrion J (2012) Hypoxic hepatitis. Liver Int 32:1039–1052
Horvatits T, Trauner M, Fuhrmann V (2013) Hypoxic liver injury and cholestasis in critically ill patients. Curr Opin Crit Care 19:128–132
Stevens RD, Pronovost PJ (2006) The spectrum of encephalopathy in critical illness. Semin Neurol 26:440–451
Clemmesen JO, Larsen FS, Kondrup J et al (1999) Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 29:648–653
Werdan K, Ruß M, Buerke M et al (2011) Deutsch-österreichische S3-Leitlinie „Infarktbedingter kardiogener Schock – Diagnose, Monitoring und Therapie“. Kardiologe 5:166–224
Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228
Taura P, Fuster J, Mercadal J et al (2010) The use of beta-adrenergic drugs improves hepatic oxygen metabolism in cirrhotic patients undergoing liver resection. J Hepatol 52:340–347
Badawi O, Waite MD, Fuhrman SA et al (2012) Association between intensive care unit-acquired dysglycemia and in-hospital mortality. Crit Care Med 40:3180–3188
Stravitz RT, Kramer AH, Davern T et al (2007) Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med 35:2498–2508
Mesotten D, Wauters J, Van Den Berghe G et al (2009) The effect of strict blood glucose control on biliary sludge and cholestasis in critically ill patients. J Clin Endocrinol Metab 94:2345–2352
El Banayosy A, Kizner L, Schueler V et al (2004) First use of the Molecular Adsorbent Recirculating System technique on patients with hypoxic liver failure after cardiogenic shock. ASAIO J 50:332–337
Acharya SK, Bhatia V, Sreenivas V et al (2009) Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology 136:2159–2168
Russo L, Gracia-Sancho J, Garcia-Caldero H et al (2012) Addition of simvastatin to cold storage solution prevents endothelial dysfunction in explanted rat livers. Hepatology 55:921–930
Llacuna L, Fernandez A, Montfort CV et al (2011) Targeting cholesterol at different levels in the mevalonate pathway protects fatty liver against ischemia-reperfusion injury. J Hepatol 54:1002–1010
Brienza N, Dalfino L, Cinnella G et al (2006) Jaundice in critical illness: promoting factors of a concealed reality. Intensive Care Med 32:267–274
Sherlock S (1998) Overview of chronic cholestatic conditions in adults: terminology and definitions. Clin Liver Dis 2:217–233, vii
Helftenbein A, Windolf J, Sanger P et al (1997) Incidence and prognosis of postoperative jaundice in surgical intensive care patients. Chirurg 68:1292–1296
Zhai R, Sheu CC, Su L et al (2009) Serum bilirubin levels on ICU admission are associated with ARDS development and mortality in sepsis. Thorax 64:784–790
Laing F (2008) Jaundice. In: Bluth E, Benson C, Ralls P, Siegel M (Hrsg) Ultrasound: a practical approach to clinical problems. Thieme, New York, S 17–35
Berzosa M, Davies SF, Gupta K et al (2013) Diagnostic bedside EUS in the intensive care unit: a single-center experience. Gastrointest Endosc 77:200–208
Te Boekhorst T, Urlus M, Doesburg W et al (1988) Etiologic factors of jaundice in severely ill patients. A retrospective study in patients admitted to an intensive care unit with severe trauma or with septic intra-abdominal complications following surgery and without evidence of bile duct obstruction. J Hepatol 7:111–117
Trauner M, Baghdasaryan A, Claudel T et al (2011) Targeting nuclear bile acid receptors for liver disease. Dig Dis 29:98–102
Recknagel P, Gonnert FA, Westermann M et al (2012) Liver dysfunction and phosphatidylinositol-3-kinase signalling in early sepsis: experimental studies in rodent models of peritonitis. PLoS Med 9:e1001338
Vanwijngaerden YM, Langouche L, Brunner R et al (2013) Withholding parenteral nutrition during critical illness increases plasma bilirubin but lowers the incidence of biliary sludge. Hepatology
Kreymann KG, Berger MM, Deutz NE et al (2006) ESPEN Guidelines on enteral nutrition: intensive care. Clin Nutr 25:210–223
Cullen SN, Rust C, Fleming K et al (2008) High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 48:792–800
Ruemmele P, Hofstaedter F, Gelbmann CM (2009) Secondary sclerosing cholangitis. Nat Rev Gastroenterol Hepatol 6:287–295
Trauner M, Fickert P, Wagner M (2007) MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis 27:77–98
Einhaltung ethischer Richtlinien
Interessenkonflikt. A. Drolz, T. Horvatits und K. Roedl geben an, dass kein Interessenkonflikt besteht. V. Fuhrmann erhielt Forschungsunterstützung von Baxter/Gambro und war für Baxter/Gambro als Referent tätig. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Drolz, A., Horvatits, T., Roedl, K. et al. Schockleber und Cholestase beim kritisch Kranken. Med Klin Intensivmed Notfmed 109, 228–234 (2014). https://doi.org/10.1007/s00063-013-0320-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00063-013-0320-5